Search

The Selux Next-Generation Phenotyping (NGP) system (Charlestown, MA) is a new antimicrobial susceptibility testing system that utilizes two sequential assays performed on all wells of doubling dilution series to determine MICs. A multicenter evaluation of the performance of the Selux NGP system compared with reference broth microdilution was conducted following FDA recommendations and using FDA-defined breakpoints. A total of 2,488 clinical and challenge isolates were included; gram-negative isolates were tested against 24 antimicrobials, and gram-positive isolates were tested against 15 antimicrobials. Data is provided for all organism-antimicrobial combinations evaluated, including those that did and did not meet FDA performance requirements. Overall very major error and major error rates were less than 1% (31/3,805 and 107/15,606, respectively), essential agreement and categorical agreement were >95%, reproducibility was ≥95%, and the average time-to-result (from time of assay start to time of MIC result) was 5.65 hours., Competing Interests: Authors K.F., B.R.S., K.R.B., S.M., K.R., A.E., M.S., J.C., J.L., K.D., N.S., G.K., F.C., J.D., A.C., A.L., J.S., K.M., A.V., and E.S. are or have been employed by Selux Diagnostics. A.F., J.S.L., M.J.F., S.E.S., M.P.W., and D.C.H. have consulted for Selux Diagnostics.